The United Kingdom and the United States have finalized a landmark trade agreement that will keep no import taxes on British medicine products going into the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to raise expenditure on drugs through the National Health Service (NHS). This move secures that import taxes on these crucial exports will be held at nothing for a timeframe of three years.
This deal comes after earlier threats to significantly raise tariffs on patented pharmaceutical imports, with figures mentioned reaching double the cost.
"This agreement with the UK reinforces the international landscape for innovative medicines and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," a release said.
Economic Importance
Pharmaceuticals are one of the UK's largest export categories to the United States, which is easily the biggest market for major British pharmaceutical firms.
Export figures indicate that in the 12 months leading up to last September, the UK sold medicines totaling over eleven billion pounds to the US. This value accounted for 17.4% of total UK exports in that period.
"This deal protects employment, stimulates investment and facilitates the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Key NHS Changes
The pact involves several key commitments from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to raise overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to prevent overspending will be capped at 15%. Previously, rebates topped twenty percent.
Industry Background
The deal takes place against a long-running row between the drug companies and the ministers over medicine costs and approval rates.
These tensions were heightened by claims that US customers were paying significantly more for the identical medicines than people in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or abandoned, while major funding commitments have been directed toward US facilities.
One official stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the past decade.
